Associations between inflammatory marker profiles and neurocognitive functioning in people with schizophrenia and non-psychiatric comparison subjects

• Published in: Journal of psychiatric research Vol. 149; pp. 106 - 113
• Main Authors: Adamowicz, David H., Shilling, Paul D., Palmer, Barton W., Nguyen, Tanya T., Wang, Eric, Liu, Chenyu, Tu, Xin, Jeste, Dilip V., Irwin, Michael R., Lee, Ellen E.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.05.2022
• Subjects: Biomarkers; Brain-Derived Neurotrophic Factor; C-Reactive Protein - metabolism; Chemokines; Cognition; Cytokines; Executive function; Humans; Inflammation - complications; Intercellular Adhesion Molecule-1; Interleukin-6; Neuropsychological Tests; Psychotic disorders; Schizophrenia; Serum Amyloid A Protein; Psychotic disorders; Executive function; Cytokines; Chemokines
• ISSN: 0022-3956; 1879-1379; 1879-1379
• DOI: 10.1016/j.jpsychires.2022.02.029

Cognitive dysfunction in schizophrenia is the key predictor of functional disability and drives economic burden. Inflammation has been increasingly implicated in the pathogenesis of schizophrenia, yet its role in cognitive decline has not been evaluated. This study explores the association between inflammation and cognitive functioning in persons with schizophrenia. Participants included 143 persons with schizophrenia (PwS) and 139 non-psychiatric comparison subjects (NCs) from an ongoing study of aging. Cognitive assessments included validated measures for executive functioning, processing speed, and visuospatial skills. Plasma levels of nine biomarkers associated with inflammation (high sensitivity C-reactive protein, intercellular adhesion molecule 1, serum amyloid A, interleukin-6, interleukin-8, interferon gamma-induced protein-10, monocyte chemotactic protein-1, fractalkine, and brain-derived neurotrophic factor) were quantified using commercially available, enzyme-linked immunosorbent assays. Partial least squares regression was used to develop a composite “inflammatory profile” to maximize correlations with the cognitive outcomes. We then constructed a best-fit model using these composites and their interactions with diagnosis and sex as the predictors, controlling for covariates. The biomarker composite, which best correlated with scores on cognitive testing, included high sensitivity C-reactive protein, intercellular adhesion molecule 1, serum amyloid A, interleukin-6, and brain-derived neurotrophic factor, for a 5-biomarker “inflammatory profile.” The best-fit model showed a significant biomarker composite by diagnosis by sex three-way interaction, for executive function and processing speed, but not visuospatial skill. This approach to building an “inflammatory profile” may provide insight into inflammatory pathways affecting brain function and potential targets for anti-inflammatory interventions to improve cognition in schizophrenia.